Kiniksa Pharmaceuticals/$KNSA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Ticker
$KNSA
Sector
Primary listing
Employees
366
Headquarters
Website
KNSA Metrics
BasicAdvanced
$4.4bn
63.48
$0.91
-
-
Price and volume
Market cap
$4.4bn
52-week high
$57.72
52-week low
$24.85
Average daily volume
787k
Financial strength
Total debt to equity
1.673
Profitability
EBITDA (TTM)
94.814
Gross margin (TTM)
54.65%
Net profit margin (TTM)
9.69%
Operating margin (TTM)
12.36%
Effective tax rate (TTM)
31.07%
Revenue per employee (TTM)
$2,060,000
Management effectiveness
Valuation
Price to earnings (TTM)
63.481
Price to revenue (TTM)
5.744
Price to book
7.74
Price to tangible book (TTM)
7.96
Growth
Revenue change (TTM)
56.71%
Earnings per share change (TTM)
-485.17%
3-year revenue growth (CAGR)
47.22%
3-year earnings per share growth (CAGR)
-31.08%
What the Analysts think about KNSA
Analyst ratings (Buy, Hold, Sell) for Kiniksa Pharmaceuticals stock.
KNSA Financial Performance
Revenues and expenses
KNSA Earnings Performance
Company profitability
KNSA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kiniksa Pharmaceuticals stock?
Kiniksa Pharmaceuticals (KNSA) has a market cap of $4.4B as of May 05, 2026.
What is the P/E ratio for Kiniksa Pharmaceuticals stock?
The price to earnings (P/E) ratio for Kiniksa Pharmaceuticals (KNSA) stock is 63.48 as of May 05, 2026.
Does Kiniksa Pharmaceuticals stock pay dividends?
No, Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders as of May 05, 2026.
When is the next Kiniksa Pharmaceuticals dividend payment date?
Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals (KNSA) does not currently have a Beta indicator.